Redhill Biopharma Ltd. (NASDAQ:RDHL) Sees Large Decrease in Short Interest

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 8,372 shares, a decrease of 43.1% from the August 15th total of 14,705 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 9,188,161 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Redhill Biopharma in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Redhill Biopharma

An institutional investor recently raised its position in Redhill Biopharma stock. Gagnon Securities LLC boosted its stake in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 86,102 shares of the biotechnology company’s stock after buying an additional 68,280 shares during the period. Gagnon Securities LLC owned approximately 1.68% of Redhill Biopharma worth $89,000 at the end of the most recent quarter. 7.20% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Trading Down 4.4%

NASDAQ:RDHL traded down $0.03 during trading hours on Wednesday, reaching $0.55. The company had a trading volume of 215,328 shares, compared to its average volume of 5,600,255. Redhill Biopharma has a 52 week low of $0.54 and a 52 week high of $2.79. The firm has a market cap of $3.34 million, a price-to-earnings ratio of 0.00 and a beta of 4.96. The firm’s 50 day moving average price is $0.66 and its 200-day moving average price is $0.81.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.